RYTM · Rhythm Pharmaceuticals Inc
United States · RS rating 31 · As of 2026-11-03
| Price | 86.44 USD |
|---|---|
| 1-day change | -7.5% |
| RS rating (overall / 1M / 3M / 12M) | 31 / 42 / 29 / 34 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 47 / 8 / 27 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +11.0% |
| Sales growth Q/Q | +11.6% |
| Distance from 52-week high | +26.5% |
| Market cap (USD) | $5.8B |